Talking Points

By TCTMDScience

Talking Points episodes

October 14 The BHF PROTECT-TAVI Trial
Can routine cerebral embolic protection reduce stroke risk in TAVI? Rajesh Kharbanda and C. Michael Gibson discuss.
6 min
September 16 The FAME 3 Trial
William Fearon and C. Michael Gibson break down the final 5-year follow-up of the study comparing FFR-guided PCI vs CABG for patients with three-vessel CAD.
10 min
September 02 The TRILUMINATE Pivotal Trial
Saibal Kar and C. Michael Gibson look at the 2-year outcomes of transcatheter edge-to-edge repair for tricuspid regurgitation.
9 min
August 05 The PRAGUE-25 Study
Pavel Osmancik and C. Michael Gibson discuss whether catheter ablation is superior to risk factor modification with antiarrythmic drugs for the treatment of AF.
8 min
July 22 The BETAMI-DANBLOCK Trial
How does discontinuing beta-blockers after MI affect outcomes in patients without HF? Dan Atar and C. Michael Gibson break it down.
9 min
July 01 New York Valves 2026: Implications of the Proposed National Coverage Determination for TAVI
In one of the most thought-provoking sessions at New York Valves 2026, Michael Mack and Roxana Mehran moderate a panel discussion looking at the future of TAVI from all angles.
1 hr 34 min
June 03 The PROCTOR Trial
Ruben de Winter and C. Michael Gibson compare clinical outcomes of native vessel versus SVG PCI for patients with prior CABG.
9 min
May 20 The SELUTION DeNovo Trial
Christian M. Spaulding and C. Michael Gibson look at the 1-year results from the study comparing sirolimus-eluting DCB with DES for de novo coronary lesions.
6 min
May 06 The VESALIUS-CV Trial
Paul Burton and C. Michael Gibson discuss the effects of adding evolocumab for patients at high risk for CV events but without prior MI or stroke.
8 min
April 22 The META-AF Trial
Amrish Deshmukh talks to C. Michael Gibson about the use of metformin as an adjunctive therapy to catheter ablation of AF.
5 min